Relative Bioavailability of a Single Oral Dose of BI 113823 (50 mg qd) When Administered Alone or in Combination With Multiple Oral Doses of Ketoconazole (200 mg Bid) in Healthy Male Volunteers (an Open Label, Two Periods, Fixed-sequence, Clinical Phase I Study).
Latest Information Update: 08 Nov 2013
At a glance
- Drugs BI 113823 (Primary) ; Ketoconazole
- Indications Osteoarthritis
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim Pharmaceuticals
Most Recent Events
- 23 Oct 2010 New trial record